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Purpose: To investigate clinicopathological characteristics
and outcomes of male breast cancer (MBC). Patients and
Methods: We retrospectively analyzed the data of 20 MBC
patients in comparison with female ductal carcinoma treated
at Yonsei University Severance Hospital from July 1985 to
May 2007. Clinicopathological features, treatment patterns,
and survival were investigated. Results: MBC consists of
0.38% of all breast cancers. The median age was 56 years.
The median symptom duration was 10 months. The median
tumor size was 1.7 cm, 27.8% showed node metastasis, and
71.4% were estrogen receptor positive. All 20 cancers were
arisen from ductal cells. No lobular carcinoma was found. The
incidence of stages 0, I, II, and III in patients were 2, 10, 4,
and 3, respectively. All patients underwent mastectomy. One
with invasive cancer did not receive axillary node dissection
and stage was not exactly evaluated. Adjuvant treatments
were determined by pathologic parameters and stage. Clinico-
pathological parameters and survival rates of MBC were
comparable to those of female ductal carcinoma. Conclusion:
The onset age of MBC was 10 years older and symptom
duration was longer than in female patients. No difference in
outcomes between MBC and female ductal carcinoma
suggests that the biology of MBC is not different from that
of females. Therefore, education, an appropriate system for
early detection, and adequate treatment are necessary for
improving outcomes.
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INTRODUCTION
Male breast cancer (MBC) is a rare disease and
accounts for less than 1% of all cases of malignancy
in men.1 The incidence of MBC has significantly
increased from 0.86 to 1.08 per 100,000 population
over the past 26 years in the United States.2 In
Korea, MBC constitutes 0.4 - 0.6% of all breast
cancers (BC).3-5 Because of its low incidence, MBC
has not been studied as extensively as female
breast cancer. Most studies related to MBC are
retrospective analyses with a small number of
patients. Appropriate management guidelines for
MBC have not yet been clearly established, and
limited information is available regarding the
epidemiology, treatment, and prognosis of the
disease.6 Therefore, the treatment guideline has
been extrapolated from the data based on female
breast cancer.
However, the incidence of MBC has been
increasing significantly along with the increasing
incidence of female breast cancer, although
geographic variations in the incidence of MBC was
reported.
2,7,8
In Europe, approximately 1% of all BC
occurs in males, but the incidence is much higher
in other areas such as sub-Saharan Africa with
15%.
9,10
Therefore, the study of MBC will become
more important every day. In this study, we
investigated clinicopathological characteristics,
treatment patterns, and outcomes of MBC in
Koreans.
PATIENTS AND METHODS
We retrospectively reviewed the medical records
of 20 MBC patients who had been treated at the
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Department of Surgery, Yonsei University College
of Medicine, in Seoul, Korea, between July 1985
and May 2007. This sample represents 0.38% (20/
5,229) of all BC treated at our institution during
the same period. Data regarding general charac-
teristics of patients (age, presenting signs and
symptoms, duration of symptoms, and site and
location of tumor), histopathology of primary
tumor, treatment modalities (surgery, chemotherapy,
radiation and hormone therapy), disease-free
survival, and overall survival were obtained by
reviewing medical records. Tumor stage was based
on the 6th American Joint Committee on Cancer
(AJCC) criteria. Histological type and grading
followed the World Health Organization (WHO)
classification. Ten percent or more of positively
stained cells was used as the cut-off for hormonal
receptor positivity. Clinical follow-up included
history taking, physical examination, laboratory
tests and radiologic imaging tests every 6 - 12
months for detection of relapse. The differences
between MBC and female ductal carcinoma were
also investigated. Chi-square test was employed to
confirm statistical significance. Disease-free sur-
vival and overall survival were estimated and
plotted using Kaplan-Meier method. Group dif-
ferences in survival time were tested by log- rank
test. A p value < 0.05 was considered statistically
significant. SPSS for Windows (ver. 13.0, SPSS Inc.,
Chicago, IL, USA) was used for all statistical
analyses.
RESULTS
General characteristics of patients
General characteristics of patients are summarized
in Table 1. The median age at diagnosis was 56
years (range, 22 - 78 years). Fifteen patients (75%)
were diagnosed after the age of 50 years and 6
were diagnosed during their 50s. Three patients
had a history of alcohol drinking and 4 had a
history of smoking. One patient diagnosed at 22
years of age had a family history of BC and his
mother died of BC when he was 2 years old. Two
patients had synchronous double primary tumors;
1 had poorly differentiated epidermoid carcinoma
of the tonsil and the other had adenocarcinoma ex
pleomorphic adenoma of the submandibular
gland. There was no history of bilateral BC. The
most common symptom was a palpable mass (n
= 18), and the median duration of symptoms was
10 months. One patient had nipple discharge for
more than 10 years. Six of the 20 patients had
cancer in the left breast and 14 in the right. Most
tumors were located in the central subareolar area
(n = 17). In 2 patients, the tumor was located in the
upper outer quadrant and in the lower inner
quadrant in 1 patient.
Histopathological characteristics of tumor
Histopathological characteristics of primary
tumor are summarized in Table 2. All 20 cases were
Table 1. General Characteristics of Male Breast Cancer
Patients
Characteristics Patients (n = 20) %
Age (yrs)
20 - 29 2 10
30 - 39 1 5
40 - 49 2 10
50 - 59 6 30




Nipple discharge 2 10
Duration of symptom
Sx 6 mo 8 40
6 mo < Sx 12 mo 6 30
12 mo < Sx 24 mo 3 15






Other quadrant 3 15
Sx, symptom; mo, month.
Table 2. Histopathological Characteristics and Treatment Patterns of Male Breast Cancer Compared to Female Ductal
Carcinoma
Characteristics Male breast cancer (%) Female ductal carcinoma (%) p value
Age (yrs) 0.002
< 50 5 (25.0) 2,743 (59.0)
50 15 (75.0) 1,905 (41.0)
Tumor size NS
2 cm 12 (60.0) 1,638 (53.5)
> 2 cm 8 (40.0) 1,421 (46.5)
Lymph node NS
Negative 13 (72.2) 2,692 (58.5)
Positive 5 (27.8) 1,908 (41.5)
Stage* NS
0 2 (10.5) 453 (9.8)
I 10 (52.6) 1,334 (28.9)
II 4 (21.1) 1,916 (41.5)
III/IV 3 (15.8) 915 (19.8)
Estrogen receptor NS
Negative 4 (28.6) 1,403 (36.4)
Positive 10 (71.4) 2,452 (63.6)
Progesterone receptor NS
Negative 6 (42.9) 1,602 (42.3)
Positive 8 (57.1) 2,184 (57.7)
Histologic grade NS
I 3 (25.0) 762 (23.2)
II/III 9 (75.0) 2,520 (76.8)
Operation method 0.014
BCS 0 (0) 1,087 (23.4)
Mastectomy 20 (100) 3,561 (76.6)
Chemotherapy 0.001
Not done 14 (70.0) 1,573 (34.6)
Done 6 (30.0) 2,976 (65.4)
Radiation therapy NS
Not done 13 (72.2) 2,810 (63.2)
Done 5 (27.8) 1,633 (36.8)
Hormone therapy NS
Not done 4 (25.0) 2,023 (45.3)
Done 12 (75.0) 2,438 (54.7)
NS, not significant; BCS, breast-conserving surgery.
*One male with invasive cancer did not receive axillary node dissection and stage was not exactly evaluated.
Histopathologic reports of estrogen receptor/progesterone receptor and grade were not documented in 6 and 8 male patients,
respectively.
We are not able to verify whether 2 and 4 male patients received radiotherapy and hormone therapy, respectively, or not.
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ductal cell in origin. The most frequent histologic
type was infiltrating ductal carcinoma (n = 14).
Four patients (20%) had special type ductal
carcinoma; 2 had tubular carcinoma, 1 had mucinous
carcinoma, and 1 had papillary carcinoma. Two
patients (10%) had non-invasive carcinoma. The
median size of the tumor was 1.7 cm (range, 0.5 -
4 cm) and 12 cases (60%) were categorized as T1
lesions. Five of the 18 patients who underwent
axillary node dissection (27.8%) showed lymph
node metastasis in the axillary area. The median
number of axillary lymph nodes removed was 19.5
(range, 8 - 34). The median number of axillary
lymph nodes involved was 4 (range, 1 - 16) among
patients with axillary lymph node metastasis. One
patient had 16 axillary lymph nodes involved.
According to the TNM staging system, there were
2, 10, 4, and 3 patients in stages 0, I, II, and III,
respectively. One with invasive cancer did not
receive axillary node dissection and stage was not
exactly evaluated. In terms of histologic grade, 3
patients had a well-differentiated tumor and 9 had
a moderately to poorly differentiated tumor.
Among 14 patients available for hormone receptors
assays, the estrogen receptor was positive in 10
patients (71.4%) and the progesterone receptor was
positive in 8 (57.1%). The status of c-erbB-2 was
available in 12 patients, 3 (25%) of whom were
positive.
Treatment patterns
Treatment patterns are summarized in Table 2.
Of the 20 patients, 18 underwent modified radical
mastectomy, 1 simple mastectomy, and 1 subcu-
taneous mastectomy. No patients received neoad-
juvant chemotherapy. After completion of surgery,
adjuvant therapies were administered: 6 received
chemotherapy, 4 CMF (cyclophosphamide, metho-
trexate, fluorouracil) regimen, and 2 anthracycline
based chemotherapy. Radiation therapy was done
in 5 patients with a mean dose of 50 grays (Gy).
Twelve patients daily received hormone therapy
with 20 mg of tamoxifen.
Survival
The median period of follow-up was 53 months
(range, 6 - 209 months). There were no local or
regional recurrences, however, there were 2
systemic metastasis and 4 deaths during follow-up.
The 5- and 10-year disease-free survival rate was
91.7% and 82.5%, respectively (Fig. 1), whereas the
5- and 10-year overall survival rate was 85.6% and
76.0%, respectively (Fig. 2). Although survival was
not significantly different, older age, larger size,
axillary lymph node metastasis, advanced tumor
stage, hormone receptor negativity, and higher
grade showed a trend for poor overall survival in
Fig. 1. Disease-free survival curve. The dotted line
represents male breast cancer and the bold line represents
female ductal carcinoma.
Fig. 2. Overall survival curve. The dotted line represents
male breast cancer and the bold line represents female
ductal carcinoma.
Table 3. 10-year Disease-free Survival and 10-year Overall Survival According to Clinicopathological Characteristics
in Male Breast Cancer
Characteristics 10-yr disease-free survival 10-yr overall survival p value
Age (yrs) NS
< 50 (n = 5) 80.0 80.0
50 (n = 15) 83.3 72.0
Tumor size NS
2 cm (n = 12) 80.0 88.9
> 2 cm (n = 8) 83.3 62.5
Lymph node NS
Negative (n = 13) 83.3 90.0
Positive (n = 5) 67.7 66.7
Stage* NS
0/I (n = 12) 83.3 90.0
II/III (n = 7) 75.0 75.0
Estrogen receptor NS
Negative (n = 4) 75.0 75.0
Positive (n = 10) 66.7 100
Progesterone receptor NS
Negative (n = 6) 75.0 75.0
Positive (n = 8) 66.7 100
Histologic grade NS
I (n = 3) 100 100
II/III (n = 9) 66.7 66.7
Chemotherapy NS
Not done (n = 14) 87.5 79.5
Done (n = 6) 66.7 66.7
Radiation therapy§ NS
Not done (n = 13) 83.3 90.0
Done (n = 5) 66.7 33.3
Hormone therapy§ NS
Not done (n = 4) 100 75.0
Done (n = 12) 75.0 75.0
NS, not significant.
*One male with invasive cancer did not receive axillary node dissection and stage was not exactly evaluated.
Histopathologic reports of estrogen receptor/progesterone receptor and grade were not documented in 6 and 8 male patients,
respectively.
5-yr disease-free survival rate was compared.
§
We are not able to verify whether 2 and 4 male patients received radiotherapy and hormone therapy, respectively, or not.
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our study (Table 3).
As mentioned above, there were 4 deaths during
follow-up. The first patient was 22 years old at
diagnosis. He had a history of familial BC and had
a stage IIa tumor. He received adjuvant chemo-
therapy with CMF regimen and radiotherapy.
However, he developed systemic metastasis and
died of BC after a follow-up period of 38 months.
The second patient was 51 years old at diagnosis.
He had stage I BC and also stage IV tonsilar cancer.
He received radiation therapy to the head and
neck area. After 20 months, he died probably of
recurrent tonsilar cancer. The third patient was 53
years old at diagnosis and had stage I tumor. He
received adjuvant hormonal therapy. However,
systemic metastases in the bones and lung were
found at 61 and 71 months after surgery, respec-
tively. He finally died of BC at 138 months after
surgery. The last patient was 63 years old at
diagnosis. He did not receive axillary lymph node
dissection. The tumor size was 2.5 cm. He received
radiation and hormonal therapy. He died at 78
months after surgery without evidence of recur-
rence.
Comparison with female ductal carcinoma
To evaluate outcomes of MBC, we compared
MBC to female ductal carcinoma, which is the
most frequent type of female breast cancer. We
retrospectively analyzed 4,648 female ductal
carcinoma patients whose last follow-up data were
available during the same period. The results are
summarized in Table 2.
MBC patients were older at diagnosis than
female ductal carcinoma patients. The median age
of female ductal carcinoma patients was 47 years.
No breast-conserving surgery was performed in
males. Other factors such as tumor size, lymph
node, stage, steroid receptors, histologic grade,
radiotherapy, and hormone therapy were not
different between the 2 groups. The median tumor
size of female ductal carcinoma was 2 cm and was
not significantly different from that of MBC. Fewer
male patients had axillary lymph node metastasis
and more had estrogen receptor positivity. Chemo-
therapy was more frequently employed in female
ductal carcinoma, and hormone therapy was more
frequently applied in MBC. The incidence rate of
stage 0 in-situ carcinoma of males was comparable
to that of females.
The 5- and 10-year disease-free survival rate of
female ductal carcinoma was 81.7% and 75.8%,
respectively (Fig. 1), whereas the 5- and 10-year
overall survival rate of female ductal carcinoma
was 86.3% and 76.2%, respectively (Fig. 2). Sur-
vival rates were not statistically different between
MBC and female ductal carcinoma. There was no
different pattern in subgroup analysis dividing
female ductal carcinoma into premenopausal and
postmenopausal when compared with MBC. The
10-year disease-free and overall survival rates of
premenopausal ductal carcinoma patients were
74.3% and 77.1%, respectively, while the 10-year
disease-free and overall survival rates of postme-
nopausal ductal carcinoma patients were 78.3%
and 74.7%, respectively.
DISCUSSION
The incidence of MBC varies widely between
countries. MBC accounts for 1.2% of newly diag-
nosed BC in the United States and approximately
1% of all BC in Europe.9-11 However, the incidence
is much higher in sub-Saharan Africa with 15% of
all BC, and the relatively high incidence is
attributed to possible hyperestrogenism as a result
of liver damage from endemic infectious disease.10
In our study, the incidence of MBC was 0.38%, and
it has been reported as 0.4 - 0.6% of all BC in
Korea.3-5 It is quite low and comparable to that in
Western countries despite the high prevalence of
viral hepatitis B infection in men (5.1%), according
to the 1998 National Health and Nutrition Survey
in Korea.12 MBC accounts for 0.49% of all cases
during 1975 - 1997 in Osaka, Japan.
13
The incidence
of MBC may be lower in Asia than in the West
due to biological and/or environmental factors,
since the incidence of female breast cancer is much
higher in Western countries.14
MBC in Western countries was presented mostly
in their 60s (range, 63 - 68 years), which is 10 years
later than in females.9,13,15 However, as in female
breast cancer, the onset of MBC in Korea is 10
years earlier than in Western countries and
appears to peak in their 50s.3,4,9 The median
duration of symptoms before diagnosis was 10
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months, which was a little longer than that in
Western countries,16 but it was significantly shorter
than what was reported 18 years ago in Korea.17
The shortened symptom duration may be asso-
ciated with general improvements in quality of life
and awareness, which can affect the outcome of
disease.
Ductal carcinoma in situ accounts for 5 - 10% of
all breast tumors in men, and the most common
growth pattern is papillary subtype.2,15,18 Infil-
trating ductal carcinoma is the most frequent
invasive carcinoma in men, accounting for 70 - 95%
of MBC, and lobular carcinoma is rare (around 1%
of all cases) due to lack of terminal lobules in the
male breast.1,2,15,18,19 Our study showed that 2 out
of 20 patients (10%) had non-invasive cancers and
the others (90%) were invasive cancers of ductal
cell origin including special type histology, but
there was no case of lobular type. These results are
compatible with previous studies.1,2,15,18,19
The expressions of estrogen and progesterone
receptor in MBC are higher than in female breast
cancer, and they have been reported to be 81 -
90.6% and 74 - 81.2%, respectively.16,20 In our study,
the expressions of estrogen and progesterone
receptor in MBC were little higher than in female
breast cancer, but it was 10 - 20% lower than that
in Western populations.
The etiology of MBC is unclear, however, many
risk factors, including hormonal imbalance, and
genetic, environmental and epidemiologic factors,
have been associated with MBC. Abnormalities in
estrogen and androgen balance may play an
important role in the development of disease.
1,18,19
Although there is high prevalence of liver injury
from viral hepatitis B infection in Korea, the inci-
dence of MBC was low. Increasing age, Ashkenazi
Jewish ancestry, African-American ethnicity, pre-
vious chest wall irradiations, alcohol drinking, and
benign breast conditions such as nipple discharge,
breast cysts, and breast trauma have been sug-
gested as risk factors.21-25 It is unclear whether
gynecomastia is a risk factor for MBC.18,19,26
The most common surgical treatment for MBC
is modified radical mastectomy, which has
displaced radical mastectomy with no significant
difference in survival.15,16,19 Unlike in female breast
cancer, however, lumpectomy probably does not
play an important role in the treatment of MBC,
because of small volume of male breast tissue.1,16
For invasive breast cancer, axillary lymph node
assessment is usually performed either via sentinel
node biopsy or axillary sampling/clearance.16,19 As
the validation, sentinel lymph node biopsy is
established as an accurate and low morbid pro-
cedure in female breast cancer, and sentinel node
biopsy plays an important role in MBC and is
being currently advocated as the standard surgical
procedure.8 Recently, one patient underwent
sentinel node biopsy. In our study, 2 patients did
not receive axillary node dissection: One patient
had intraductal papillary carcinoma, and is still
alive and disease-free at more than 108 months
after surgery. The other had invasive papillary
carcinoma of 2.5 cm in diameter and received
radiation and hormone therapy, however, he died
of unknown causes at 78 months after surgery.
Although adjuvant chemotherapy and hormonal
therapy have proven benefits for a subgroup of
female breast cancer patients, the role of adjuvant
chemotherapy in MBC is less clear.1 Adjuvant
chemotherapy in MBC can usually be decided by
assessing the risks and benefits in the same
manner as in female breast cancer.1,15,16,27 Because
of high expression rates of hormone receptor
positivity in MBC, adjuvant hormone therapy with
tamoxifen is theoretically the rational therapeutic
strategy and should be considered in men with
BC.1,15,16,27 In several retrospective studies, tamo-
xifen increased disease-free survival and overall
survival in MBC patients.28,29 Although aromatase
inhibitors recently showed improved survival for
postmenopausal women with BC,
30
aromatase
inhibitors alone may be problematic because 20%
of circulating estrogens are produced by testes in
men independent of aromatase.15,16
In general, men with BC had a longer duration
of symptoms than women, and subsequent delay
in diagnosis contributes to advanced stage.1,27
Tumor size and axillary lymph node involvement
are the most important prognostic factors for male
and female breast cancer.20,31 When matched for
age and stage, men and women have similar pro-
gnoses.
2,20
In Korea, it has been reported that the
5- and 10-year observed overall survival rate of
female patients with breast cancer was 84.1 - 89.4%
and 70.1 - 82.9%, respectively.
4,32,33
In our study,
although the sample size was too small to have
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an exact comparison, there was no difference in
disease-free survival and overall survival between
MBC and female ductal carcinoma. Although it
was not statistically significant, older age, larger
size, axillary lymph mode metastasis, advanced
stage, higher grade, and hormone receptor negati-
vity were related to poor overall survival in MBC.
It is known that men with BC have poorer overall
survival rates than women, but this is probably
due to older age at diagnosis, more advanced stage
at presentation, and higher rates of death from
comorbid disease, but not due to the biology of
the disease itself.1,2,18,20
The 5- and 10-year survival rates of MBC have
been reported at 57% and 28%, respectively, in
1990,17 however, those in this study were improved
at 85.6% and 76.0%, respectively. The main reason
for such an improvement in 20 years could be early
detection and adequate treatment, resulting in
shortened symptom duration, smaller tumor size,
much lower incidence of axillary node involve-
ment, and increased use of tamoxifen. These
results suggest that early detection, adequate treat-
ment, and close follow-up would be the mainstay
for improving survival of MBC.
In conclusion, the tumor biology of MBC is not
significantly different from that of females,
however, limited public awareness and absence of
adequate screening for MBC result in delayed
diagnosis and poor outcomes. Therefore, educa-
tion, an appropriate system for early detection, and
adequate treatment are prerequisite for improving
outcomes, and men presenting any breast symp-
toms should be examined in the same manner and
degree of urgency as in women to detect cancer
at an early stage and better treatment outcomes.
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